biostudies-literatureOka SJapan Research Foundation for Clinical PharmacologyAstellas Pharma Inc.the Japan Society for the Promotion of ScienceNational Hospital OrganizationThe Nakatomi FoundationAbbott Japan Co., Ltd.the Ministry of Health, Labour, and Welfare of JapanMerck Sharp and Dohme Inc.Chugai Pharmaceutical Co., Ltd.Takeda Science FoundationMitsubishi Tanabe Pharma CorporationBristol-Myers Squibb Co.Eisai Co., Ltd.Japan Agency for Medical Research and DevelopmentMitsui Sumitomo Insurance Welfare FoundationDaiwa Securities Health FoundationTeijin Pharma LimitedPfizer Japan Inc.Takeda Pharmaceutical Company Limited363https://www.ebi.ac.uk/biostudies/studies/S-EPMC9962840biostudies-literatureUnknown59(2)Chronic lung diseases (CLD), including interstitial lung disease (ILD) and airway diseases (ADs), are common complications of rheumatoid arthritis (RA). Rheumatoid factor (RF) and anti-citrullinated peptide antibodies are reported to be associated with CLD in RA patients. The presence of anti-melanoma differentiation-associated gene 5 (MDA5) antibodies (Abs) is associated with clinically amyopathic dermatomyositis developing into rapidly progressive ILD. However, few studies on anti-MDA5 Abs in RA have been published. Here, we analyzed the association of anti-MDA5 Abs with CLD complications in RA. Anti-MDA5 Abs were quantified in sera from RA patients with or without CLD. Anti-MDA5 Ab levels were higher in RA patients with ADs than without (mean ± SDM, 4.4 ± 2.4 vs. 4.0 ± 4.2, <i>p =</i> 0Medicina (Kaunas, Lithuania)Antibodies against Serum Anti-Melanoma Differentiation-Associated Gene 5 in Rheumatoid Arthritis Patients with Chronic Lung Diseases.PMC996284022591090, 26293123, 15K09543, 18K08402Furukawa HKomiya AHashimoto AOkamoto AYoshikawa NFukui NHiguchi TShimada KMatsui TOka STohma SKatayama MSaisho KMigita KfalseAntibodies against Serum Anti-Melanoma Differentiation-Associated Gene 5 in Rheumatoid Arthritis Patients with Chronic Lung Diseases.Chronic lung diseases (CLD), including interstitial lung disease (ILD) and airway diseases (ADs), are common complications of rheumatoid arthritis (RA). Rheumatoid factor (RF) and anti-citrullinated peptide antibodies are reported to be associated with CLD in RA patients. The presence of anti-melanoma differentiation-associated gene 5 (MDA5) antibodies (Abs) is associated with clinically amyopathic dermatomyositis developing into rapidly progressive ILD. However, few studies on anti-MDA5 Abs in RA have been published. Here, we analyzed the association of anti-MDA5 Abs with CLD complications in RA. Anti-MDA5 Abs were quantified in sera from RA patients with or without CLD. Anti-MDA5 Ab levels were higher in RA patients with ADs than without (mean ± SDM, 4.4 ± 2.4 vs. 4.0 ± 4.2, <i>p =</i> 02023-01-01T00:00:00Z2023 Feb2025-04-04T21:43:15.555Z2025-04-04T21:43:15.555ZS-EPMC99628403683756610.3390/medicina59020363